Hematology/Oncology

Top Story

Health Canada approves radiopaque bead for HCC, CRC liver metastases

August 25, 2016

BTG International Canada Inc. announced it received Health Canada approval for DC Bead Lumi. The bead is the first such device available commercially for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.

“DC Bead Lumi reinforces our leadership in embolization technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients,” Brad Pearson, director of commercial operations of BTG International Canada Inc. said in a press release. “We are excited by the potential to offer a new standard of care.“

In the Journals

High drug prices result of government protection in US

August 25, 2016
The high cost of prescription drugs in the United States is the result of drug manufacturers being granted government-protected monopolies, according to data published…
In the Journals Plus

Studies review extent, disclosure of industry relationships

August 25, 2016
More than two-thirds of the authors of National Comprehensive Cancer Network clinical practice guidelines reported at least one financial conflict of interest, according…

$1 million gift establishes professorship in women’s cancers at City of Hope

August 25, 2016
A $1 million gift has established an endowed professorship in City of Hope’s women’s cancers program. Joanne Mortimer, MD, director of City of…
In the Journals Plus

Genomic risk test may guide use of chemotherapy for early-stage breast cancer

August 25, 2016
A 70-gene signature test identified a substantial portion of women with early-stage breast cancer who safely avoid chemotherapy, according to phase 3 study results…
More News Headlines »
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video
Meeting News Coverage

VIDEO: CAR T cell therapy durable, effective for treatment of acute, chronic lymphoblastic leukemia

August 12, 2016
More »
Featured
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer

CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today